English
Home > Products > 477600-75-2

China 477600-75-2 Factory

Our solutions are broadly acknowledged and dependable by users and may meet consistently developing economic and social requires for 477600-75-2,CAS NO 477600-75-2,Tofacitinib API,Tofacitinib, We welcome clients, business enterprise associations and mates from all pieces from the earth to make contact with us and request cooperation for mutual advantages.
477600-75-2, Our Company policy is "quality first, to be better and stronger, sustainable development" . Our pursuit goals is "for society, customers, employees, partners and enterprises to seek reasonable benefit". We aspirate to do cooperate with all different the auto parts manufacturers, repair shop, auto peer , then create a beautiful future! Thank you for taking time to browse our website and we would welcome any suggestions you may have that can help us to improve our site.

Related Products

Hot Products

  • TubePharm10tm

    TubePharm10tm

    Product Name:TubePharm10tm
    Molecular Formula:C27H22F2N6O5S
    Molecular Weight:580.56
    CAS Registry Number:1589503-96-7
  • Ceftiofur sodium

    Ceftiofur sodium

    Product Name:Ceftiofur sodium
    Molecular Formula:C19H18N5NaO7S3
    Molecular Weight;547.55
    CAS Registry Number;104010-37-9
  • Trimethoprim

    Trimethoprim

    Product Name:Trimethoprim
    Molecular Formula:C14H18N4O3
    Molecular Weight;290.32
    CAS Registry Number;738-70-5
  • Linezolid flucose lnjection

    Linezolid flucose lnjection

    Product Name:Linezolid flucose lnjection
    Dosage:100ml/0.2g
    Application:Antibiotic
  • MAEM

    MAEM

    Product Name:MAEM
    Molecular Formula:C13H10N4O3S2
    Molecular Weight:334.37
    CAS Registry Number:84994-24-1
  • 1-(4-iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one

    1-(4-iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one

    Product Name:1-(4-iodophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one
    Molecular Formula:C15H17IN2O2
    Molecular Weight:384.21
    CAS Registry Number:473927-69-4
  • Related Blog
  • Reviews

  • What Is Ursodeoxycholic Acid Used For?

    Ursodeoxycholic acid is a cholelithiant commonly used in the gastroenterology department, and also a cholelithiasis dissolving agent, so it can be used in the treatment of gallstones under normal circumstances, on the premise...

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 477600-75-2

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept